Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human study of CIT-013 in healthy volunteers, LPS-challenged volunteers, and patients with rheumatoid arthritis
NL-OMON56333Phase 1Completed
- Sponsor
- Citryll
- Start
- Jul 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of CIT013 in rheumatoid arthritis (RA), acute inflammatory disorder and Not applicable (8 arms), sponsored by Citryll. Started Jul 2021; status: completed.
02
Drugs
CIT013
03
Conditions
rheumatoid arthritis (RA)acute inflammatory disorderNot applicable
Beyond the preview
Go deeper on NL-OMON56333.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56333.